SRRK - Scholar Rock Holding Corp Stock Price, Fair Value and News

$43.47+2.39 (+5.82%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

SRRK Price Action

Last 7 days

0.7%

Last 30 days

51.0%

Last 90 days

34%

Trailing 12 Months

10.4%

SRRK RSI Chart

SRRK Valuation

Market Cap

4.4B

Price/Earnings (Trailing)

-12.55

Price/Sales (Trailing)

405.1

Price/Free Cashflow

-16.15

SRRK Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

SRRK Fundamentals

SRRK Revenue

Revenue (TTM)

10.9M

Rev. Growth (Yr)

31.2%

Rev. Growth (Qtr)

-19.88%

SRRK Earnings

Earnings (TTM)

-353.4M

Earnings Growth (Yr)

-58.53%

Earnings Growth (Qtr)

7.1%

SRRK Profitability

Return on Equity

-144.26%

Return on Assets

-85.84%

Free Cashflow Yield

-6.19%

SRRK Investor Care

Shares Dilution (1Y)

8.96%

Diluted EPS (TTM)

-3.16

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2025	0	8.2M	10.9M	0
2024	0	2.7M	4.8M	0
2022	47.3M	42.7M	37.2M	33.2M
2021	15.1M	15.8M	18.2M	18.8M
2020	22.4M	21.3M	19.5M	15.4M
2019	0	0	0	20.5M

Get all data in R, Python etc through our Historical Stock Data APIs

About Scholar Rock Holding Corp

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clinical trials for the treatment of spinal muscular atrophy; and SRK-181, which is in Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is also developing a pipeline of novel product candidates with potential to transform the lives of patients suffering from a range of serious diseases, including neuromuscular disorders, cancer, fibrosis, and iron-restricted anemia. The company has a collaboration agreement with Gilead Sciences, Inc. to discover and develop specific inhibitors of transforming growth factor beta activation for the treatment of fibrotic diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.

CEO	Dr. Jay T. Backstrom M.D., M.P.H.
WEBSITE	https://scholarrock.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	114

Scholar Rock Holding Corp Frequently Asked Questions

What is the ticker symbol for Scholar Rock Holding Corp? What does SRRK stand for in stocks?

SRRK is the stock ticker symbol of Scholar Rock Holding Corp. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Scholar Rock Holding Corp (SRRK)?

As of Wed Dec 03 2025, market cap of Scholar Rock Holding Corp is 4.43 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of SRRK stock?

You can check SRRK's fair value in chart for subscribers.

Is Scholar Rock Holding Corp a good stock to buy?

The fair value guage provides a quick view whether SRRK is over valued or under valued. Whether Scholar Rock Holding Corp is cheap or expensive depends on the assumptions which impact Scholar Rock Holding Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SRRK.

What is Scholar Rock Holding Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Dec 03 2025, SRRK's PE ratio (Price to Earnings) is -12.55 and Price to Sales (PS) ratio is 405.1. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SRRK PE ratio will change depending on the future growth rate expectations of investors.